Allogeneic bone marrow transplantation in beta-thalassaemia--single centre study

Area of Science:

• Hematology
• Transplantation Immunology
• Pediatric Hematology

Background:

• Beta-thalassemia is a severe inherited blood disorder requiring lifelong treatment.
• Allogeneic bone marrow transplantation (BMT) is a potentially curative option for beta-thalassemia.
• Evaluating BMT outcomes in specific healthcare settings is crucial for optimizing treatment protocols.

Purpose of the Study:

• To assess the outcomes of allogeneic BMT in patients with beta-thalassemia.
• To analyze the efficacy of different conditioning regimens based on risk stratification.
• To identify factors influencing engraftment, graft rejection, and survival post-transplant.

Main Methods:

• A cohort of 19 beta-thalassemia patients underwent allogeneic BMT from HLA-identical sibling donors.
• Patients were stratified into Class-I, Class-II, and Class-III based on the Pesaro risk classification.
• Conditioning regimens varied, including busulfan/cyclophosphamide or hydroxyurea/azathioprine/fludarabine, with GvHD prophylaxis using cyclosporine, prednisolone, and methotrexate.

Main Results:

• Engraftment was successful in all Class-I patients; one graft rejection occurred in Class-II and Class-III each.
• Median times for neutrophil, platelet, and reticulocyte recovery were 13, 15, and 15 days, respectively.
• Acute GvHD occurred in 15 patients, with one fatal case of grade IV GvHD. Infectious complications led to three deaths.

Conclusions:

• Allogeneic BMT is the sole curative treatment for beta-thalassemia.
• Careful patient selection and early transplantation significantly enhance the success rates of BMT.
• Risk stratification and appropriate conditioning are vital for improving BMT outcomes in beta-thalassemia.